Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...

Content from other channels on our network

Inverell upgrades 30-year-old aeration system

Agricultural waste to create sustainable textiles

Sustainable shipping not a priority for retailers: report

Cleanaway acquires Citywide Waste

Grid simulation software to unlock future grid capacity

Deepfakes mimicking health professionals pose real risk

Diagnostic reference levels for mammography now a step closer

Renewal fee rebate for parental and other leave now in effect

SA reaches state-first allied health enterprise agreement

WA's Health Support Services appoints Giles Nunis CEO

Suntory Oceania’s $3bn beverage business launched in Qld

Heat and Control showcases sustainable food processing solutions

Top 5 keys to successful refrigerated transport in the last mile

Haigh's CEO announces retirement

Nestlé and IBM partner to identify novel packaging materials